{"id":60894,"date":"2024-02-28T07:13:40","date_gmt":"2024-02-28T07:13:40","guid":{"rendered":"https:\/\/medsname.com\/hertraz-injection\/"},"modified":"2026-04-30T14:45:56","modified_gmt":"2026-04-30T14:45:56","slug":"hertraz-injection","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/hertraz-injection\/","title":{"rendered":"Hertraz Injection"},"content":{"rendered":"
\n

Quick Answer<\/h3>\n

Hertraz Injection<\/strong> \u00e4r en onkologisk behandling som kr\u00e4ver specialist\u00f6vervakning \u2014 administreras under sjukhus\u00f6vervakning. L\u00e4s doserings-, biverknings- och interaktionsavsnitten nedan f\u00f6re anv\u00e4ndning; vanliga fr\u00e5gor besvaras l\u00e4ngst ner.<\/p>\n<\/div>\n

\nVad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade kundrecensioner<\/a>\n<\/div>\n

\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n

Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n

V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n

Produkt\u00f6versikt<\/strong><\/p>\n

Hertraz Injection is a medication containing the active ingredient Trastuzumab, available in vial form with a concentration of 440mg per vial. Trastuzumab is a monoclonal antibody used in the treatment of certain types of cancer, including breast cancer and gastric cancer. It is a targeted therapy that works by binding to specific receptors on cancer cells, inhibiting their growth and promoting cell death. Hertraz Injection is administered intravenously under the supervision of a healthcare professional.<\/p>\n

Anv\u00e4ndningsomr\u00e5den<\/strong><\/p>\n

Hertraz Injection is indicated for the treatment of HER2-positive breast cancer, either alone or in combination with other chemotherapy agents. It is also used in combination with other drugs to treat HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers overexpress the human epidermal growth factor receptor 2 (HER2), and Trastuzumab specifically targets these receptors to inhibit cancer cell proliferation.<\/p>\n

Hur man anv\u00e4nder<\/strong><\/p>\n

Hertraz Injection is administered as an intravenous infusion by a healthcare provider in a clinical setting. The dosage and infusion rate are determined based on the patient’s body weight and medical condition. Prior to administration, the vial should be inspected visually for any particulate matter or discoloration. The injection should be given over a specified period, and patients are monitored for any signs of infusion-related reactions during and after the infusion.<\/p>\n

Hur det fungerar<\/strong><\/p>\n

Trastuzumab, the active ingredient in Hertraz Injection, is a monoclonal antibody that targets and binds to the HER2 receptors present on the surface of cancer cells. By binding to these receptors, Trastuzumab inhibits downstream signaling pathways that promote cell proliferation and survival. Additionally, it can stimulate the immune system to attack HER2-positive cancer cells, further enhancing its anticancer effects. This targeted approach helps to selectively destroy cancer cells while minimizing damage to healthy tissues.<\/p>\n

Dosering och administration<\/strong><\/p>\n

The recommended dosage of Hertraz Injection varies depending on the type and stage of cancer being treated, as well as other factors such as the patient’s weight and overall health. It is typically administered intravenously every 1 to 3 weeks, with the dosage adjusted based on the patient’s tolerance and response to treatment. Treatment duration may vary, and patients should follow the dosing schedule recommended by their healthcare provider.<\/p>\n

F\u00f6rdelar<\/strong><\/p>\n